CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 1.2%

Shares of CRISPR Therapeutics AG (NASDAQ:CRSPGet Free Report) traded down 1.2% on Tuesday . The stock traded as low as $60.70 and last traded at $61.06. 265,434 shares changed hands during trading, a decline of 84% from the average session volume of 1,651,046 shares. The stock had previously closed at $61.79.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Barclays dropped their target price on CRISPR Therapeutics from $80.00 to $67.00 and set an “equal weight” rating for the company in a report on Thursday, May 9th. Oppenheimer lowered their target price on CRISPR Therapeutics from $102.00 to $95.00 and set an “outperform” rating on the stock in a research report on Friday, May 10th. Citigroup reduced their target price on CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating on the stock in a report on Thursday, May 23rd. Piper Sandler restated an “overweight” rating and set a $105.00 target price on shares of CRISPR Therapeutics in a report on Monday. Finally, Chardan Capital increased their target price on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $75.71.

View Our Latest Stock Report on CRSP

CRISPR Therapeutics Stock Performance

The business’s 50 day moving average price is $57.06 and its 200-day moving average price is $65.09. The firm has a market cap of $5.17 billion, a price-to-earnings ratio of -22.45 and a beta of 1.78.

CRISPR Therapeutics (NASDAQ:CRSPGet Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $25.53 million. During the same period in the previous year, the company posted ($0.67) earnings per share. CRISPR Therapeutics’s revenue was down 99.5% on a year-over-year basis. On average, analysts forecast that CRISPR Therapeutics AG will post -5.51 earnings per share for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 19,582 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $59.91, for a total value of $1,173,157.62. Following the completion of the sale, the chief executive officer now owns 208,122 shares in the company, valued at approximately $12,468,589.02. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 4.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CRSP. Blue Trust Inc. acquired a new position in CRISPR Therapeutics in the 4th quarter valued at $32,000. Bourgeon Capital Management LLC boosted its holdings in CRISPR Therapeutics by 1,000.0% in the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock valued at $34,000 after purchasing an additional 500 shares during the period. Riggs Asset Managment Co. Inc. boosted its holdings in CRISPR Therapeutics by 66.7% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after purchasing an additional 200 shares during the period. Principal Securities Inc. bought a new stake in CRISPR Therapeutics in the 4th quarter valued at $41,000. Finally, NBC Securities Inc. boosted its holdings in CRISPR Therapeutics by 257.6% in the 1st quarter. NBC Securities Inc. now owns 608 shares of the company’s stock valued at $41,000 after purchasing an additional 438 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

(Get Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Read More

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.